Tag: ABM Therapeutics

ABM Therapeutics begins phase 1 trial of BRAF inhibitor ABM-1310

ABM Therapeutics said that the first cancer patient has been enrolled and dosed with its lead candidate ABM-1310, a BRAF inhibitor, in a phase 1 ... Read More